Q1 2026 · 13F-HR
Venrock Adviser, LLCholdings as filed
Filed 2026-05-15 · accession 0001615982-26-000011
$2.68B
Reported value
33
Positions
2026-03-31
Period end
The Brief · Venrock Adviser, LLC · Q1 2026
AI · grounded in 13F
Venrock Adviser, LLC established a new position in DMRA valued at $93.3M. The fund also opened new stakes in RLMD for $33.7M and TENX for $26.8M. Conversely, the fund closed its entire position in UPB, resulting in a $31.7M reduction.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $714.9M | 26.7% | 8,493,321 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $265.1M | 9.89% | 16,382,812 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $203.5M | 7.60% | 4,148,428 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $185.9M | 6.94% | 3,685,448 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $130.3M | 4.86% | 6,474,485 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $99.0M | 3.70% | 1,180,000 | Common | SOLE |
| 36322Q206 | DMRA | DAMORA THERAPEUTICS INC | $93.3M | 3.48% | 3,603,595 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $87.6M | 3.27% | 10,346,926 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $77.0M | 2.87% | 2,000,000 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $75.9M | 2.83% | 3,882,709 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $75.0M | 2.80% | 13,740,375 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $67.7M | 2.53% | 1,726,331 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $54.7M | 2.04% | 4,319,765 | Common | SOLE |
| 929033207 | VOR | VOR BIOPHARMA INC | $54.3M | 2.03% | 3,041,719 | Common | SOLE |
| 578784100 | MAZE | MAZE THERAPEUTICS INC | $47.8M | 1.78% | 1,602,034 | Common | SOLE |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC | $46.9M | 1.75% | 9,982,124 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $45.2M | 1.69% | 3,220,364 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $39.4M | 1.47% | 2,173,913 | Common | SOLE |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $39.2M | 1.46% | 2,133,576 | Common | SOLE |
| G9TY5A101 | ZURA | ZURA BIO LTD | $38.3M | 1.43% | 6,434,990 | Common | SOLE |
| 75955J402 | RLMD | RELMADA THERAPEUTICS INC | $33.7M | 1.26% | 4,843,380 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $32.5M | 1.21% | 4,771,414 | Common | SOLE |
| 88032L605 | TENX | TENAX THERAPEUTICS INC | $26.8M | 1.00% | 1,675,262 | Common | SOLE |
| 00704R109 | ANL | ADLAI NORTYE LTD | $22.2M | 0.83% | 3,212,731 | Common | SOLE |
| 15673T100 | IPSC | CENTURY THERAPEUTICS INC | $19.7M | 0.73% | 8,695,652 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $19.6M | 0.73% | 1,379,965 | Common | SOLE |
| 23256X407 | HELP | CYBIN INC | $18.5M | 0.69% | 3,851,654 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN INC | $18.4M | 0.69% | 632,931 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $12.2M | 0.45% | 506,056 | Common | SOLE |
| 500946108 | KRRO | KORRO BIO INC | $11.4M | 0.43% | 1,009,500 | Common | SOLE |
| 02157Q109 | ANRO | ALTO NEUROSCIENCE INC | $11.2M | 0.42% | 500,000 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $10.4M | 0.39% | 1,609,569 | Common | SOLE |
| 98420X202 | XFOR | X4 PHARMACEUTICALS INC | $1.4M | 0.05% | 330,525 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.